Izzo AA, Sharkey KA (2010). „Cannabinoids and the gut: new developments and emerging concepts”. Pharmacology & Therapeutics. 126 (1): 21—38. PMID20117132. doi:10.1016/j.pharmthera.2009.12.005.
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006). „Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.”. Cell Metab. 3 (3): 167—175. PMID16517404. doi:10.1016/j.cmet.2006.02.004.
Swaminath G. (2008). „Fatty acid binding receptors and their physiological role in type 2 diabetes.”. Arch Pharm (Weinheim). 341 (12): 753—761. PMID19009545. doi:10.1002/ardp.200800096.
Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, Yang S, Ning Y, Del Vecchio RA, Poulet F, Laverty M, Gustafson EL, Hedrick JA, Kowalski TJ (2009). „GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.”. J Endocrinol. 201 (2): 219—230. PMID19282326. doi:10.1677/JOE-08-0453.
Swaminath G. (2008). „Fatty acid binding receptors and their physiological role in type 2 diabetes.”. Arch Pharm (Weinheim). 341 (12): 753—761. PMID19009545. doi:10.1002/ardp.200800096.
Wu Y, Kuntz JD, Carpenter AJ, Fang J, Sauls HR, Gomez DJ, Ammala C, Xu Y, Hart S, Tadepalli S (2010). „2,5-Disubstituted pyridines as potent GPR119 agonists”. Bioorganic & Medicinal Chemistry Letters. 20 (8): 2577—81. PMID20227877. doi:10.1016/j.bmcl.2010.02.083.
Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, Chu ZL, Grottick AJ, Hauser EK, Leonard J, Jones RM (2008). „Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.”. J Med Chem. 51 (17): 5172—5175. PMID18698756. doi:10.1021/jm8006867.
Jones RM, Leonard JN, Buzard DJ, Lehmann J (2009). „GPR119 agonists for the treatment of type 2 diabetes”. Expert Opin Ther Pat. 19 (10): 1339—59. PMID19780700. doi:10.1517/13543770903153878.
Izzo AA, Sharkey KA (2010). „Cannabinoids and the gut: new developments and emerging concepts”. Pharmacology & Therapeutics. 126 (1): 21—38. PMID20117132. doi:10.1016/j.pharmthera.2009.12.005.
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006). „Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.”. Cell Metab. 3 (3): 167—175. PMID16517404. doi:10.1016/j.cmet.2006.02.004.
Swaminath G. (2008). „Fatty acid binding receptors and their physiological role in type 2 diabetes.”. Arch Pharm (Weinheim). 341 (12): 753—761. PMID19009545. doi:10.1002/ardp.200800096.
Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, Yang S, Ning Y, Del Vecchio RA, Poulet F, Laverty M, Gustafson EL, Hedrick JA, Kowalski TJ (2009). „GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.”. J Endocrinol. 201 (2): 219—230. PMID19282326. doi:10.1677/JOE-08-0453.
Swaminath G. (2008). „Fatty acid binding receptors and their physiological role in type 2 diabetes.”. Arch Pharm (Weinheim). 341 (12): 753—761. PMID19009545. doi:10.1002/ardp.200800096.
Shah U (2009). „GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders”. Current Opinion in Drug Discovery & Development. 12 (4): 519—32. PMID19562648.
Wu Y, Kuntz JD, Carpenter AJ, Fang J, Sauls HR, Gomez DJ, Ammala C, Xu Y, Hart S, Tadepalli S (2010). „2,5-Disubstituted pyridines as potent GPR119 agonists”. Bioorganic & Medicinal Chemistry Letters. 20 (8): 2577—81. PMID20227877. doi:10.1016/j.bmcl.2010.02.083.
Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, Chu ZL, Grottick AJ, Hauser EK, Leonard J, Jones RM (2008). „Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.”. J Med Chem. 51 (17): 5172—5175. PMID18698756. doi:10.1021/jm8006867.
Jones RM, Leonard JN, Buzard DJ, Lehmann J (2009). „GPR119 agonists for the treatment of type 2 diabetes”. Expert Opin Ther Pat. 19 (10): 1339—59. PMID19780700. doi:10.1517/13543770903153878.